RECURSION PHARMACEUTICALS, INC. (RXRX) Stock
6 of the hedge funds AlphaScala tracks reported RXRX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $151.71M. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
Which hedge funds own RXRX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 41.34M | $151.71M | +3% |
| Marshall Wace | 4.71M | $17.30M | +64% |
| Millennium Management Israel Englander | 1.83M | $6.73M | -30% |
| Citadel Ken Griffin | 128K | $471.5K | -79% |
| D.E. Shaw David Shaw | 38K | $139.1K | -18% |
| Bridgewater Associates Ray Dalio | 38K | $138.2K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are RECURSION PHARMACEUTICALS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 6, 26 | Hershberg Robert | Director | SELL | 25.0K | $125K |
| Oct 6, 26 | Borgeson Blake | Director | SELL | 50.0K | $242K |
| Sep 8, 26 | Khan Najat | CEO and President | SELL | 22.4K | $79K |
| Sep 1, 26 | Borgeson Blake | Director | SELL | 30.0K | $100K |
| Aug 4, 26 | Borgeson Blake | Director | SELL | 30.0K | $98K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →RXRX price chart
Powered by TradingViewWhat does RECURSION PHARMACEUTICALS, INC. do?
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on decoding biology to industrialize drug discovery. It integrates technological innovations across biology, chemistry, automation, data science, engineering, artificial intelligence, and machine learning to identify novel drug candidates, mechanisms of action, novel chemistry, and potential toxicity. The company's Recursion operating system powers advanced machine learning approaches for in vivo validation and advancing therapeutics aimed at improving patient lives. Operating in the healthcare sector, specifically biotechnology, Recursion Pharmaceuticals, Inc. develops medicines through its proprietary platform that combines automation with data-driven insights. Founded in 2013 and headquartered in Salt Lake City, Utah, it emphasizes reinvesting resources into growth-oriented research and development in the competitive biotech landscape.